Sotera Health Co (SHC)

$15.36

-0.04

(-0.26%)▲

Market is closed - opens 7 PM, 10 Oct 2024

Performance

  • $15.28
    $15.47
    $15.36
    downward going graph

    0.52%

    Downside

    Day's Volatility :1.23%

    Upside

    0.71%

    downward going graph
  • $10.71
    $17.44
    $15.36
    downward going graph

    30.27%

    Downside

    52 Weeks Volatility :38.59%

    Upside

    11.93%

    downward going graph

Returns

PeriodSotera Health CoSector (Health Care)Index (Russel 2000)
3 Months
29.63%
4.7%
0.0%
6 Months
32.53%
5.9%
0.0%
1 Year
8.53%
16.3%
0.0%
3 Years
-38.99%
19.6%
-20.8%

Highlights

Market Capitalization
4.5B
Book Value
$1.49
Earnings Per Share (EPS)
0.14
PE Ratio
112.86
PEG Ratio
1.61
Wall Street Target Price
16.75
Profit Margin
3.65%
Operating Margin TTM
31.06%
Return On Assets TTM
7.66%
Return On Equity TTM
9.53%
Revenue TTM
1.1B
Revenue Per Share TTM
3.9
Quarterly Revenue Growth YOY
8.3%
Gross Profit TTM
557.0M
EBITDA
537.6M
Diluted Eps TTM
0.14
Quarterly Earnings Growth YOY
-0.62
EPS Estimate Current Year
0.72
EPS Estimate Next Year
0.84
EPS Estimate Current Quarter
0.16
EPS Estimate Next Quarter
0.2

Analyst Recommendation

Buy
    72%Buy
    27%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Sotera Health Co(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
7
6
Hold
3
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 9.05%

Current $15.36
Target $16.75

Company Financials

FY18Y/Y Change
Revenue
746.1M
-
Net Income
-5.9M
-
Net Profit Margin
-0.79%
-
FY19Y/Y Change
Revenue
778.3M
↑ 4.31%
Net Income
-20.4M
↑ 247.96%
Net Profit Margin
-2.62%
↓ 1.83%
FY20Y/Y Change
Revenue
818.2M
↑ 5.12%
Net Income
-37.5M
↑ 83.55%
Net Profit Margin
-4.58%
↓ 1.96%
FY21Y/Y Change
Revenue
931.5M
↑ 13.85%
Net Income
116.9M
↓ 411.76%
Net Profit Margin
12.55%
↑ 17.13%
FY22Y/Y Change
Revenue
1.0B
↑ 7.75%
Net Income
-233.6M
↓ 299.83%
Net Profit Margin
-23.27%
↓ 35.82%
FY23Y/Y Change
Revenue
1.0B
↑ 4.54%
Net Income
51.4M
↓ 122.0%
Net Profit Margin
4.9%
↑ 28.17%
Q1 FY23Q/Q Change
Revenue
220.6M
↓ 12.32%
Net Income
2.8M
↓ 100.89%
Net Profit Margin
1.29%
↑ 128.37%
Q2 FY23Q/Q Change
Revenue
255.3M
↑ 15.73%
Net Income
23.5M
↑ 727.34%
Net Profit Margin
9.21%
↑ 7.92%
Q3 FY23Q/Q Change
Revenue
263.2M
↑ 3.09%
Net Income
-13.7M
↓ 158.1%
Net Profit Margin
-5.19%
↓ 14.4%
Q4 FY23Q/Q Change
Revenue
310.2M
↑ 17.88%
Net Income
38.7M
↓ 383.17%
Net Profit Margin
12.47%
↑ 17.66%
Q1 FY24Q/Q Change
Revenue
248.2M
↓ 20.0%
Net Income
6.3M
↓ 83.65%
Net Profit Margin
2.55%
↓ 9.92%
Q2 FY24Q/Q Change
Revenue
276.6M
↑ 11.45%
Net Income
8.8M
↑ 38.45%
Net Profit Margin
3.16%
↑ 0.61%
FY18Y/Y Change
Total Assets
2.7B
-
Total Liabilities
2.7B
-
FY19Y/Y Change
Total Assets
2.6B
↓ 4.72%
Total Liabilities
3.2B
↑ 20.98%
FY20Y/Y Change
Total Assets
2.8B
↑ 7.0%
Total Liabilities
2.3B
↓ 28.4%
FY21Y/Y Change
Total Assets
2.8B
↑ 1.02%
Total Liabilities
2.2B
↓ 4.48%
FY22Y/Y Change
Total Assets
3.1B
↑ 11.77%
Total Liabilities
2.8B
↑ 25.6%
FY23Y/Y Change
Total Assets
3.1B
↑ 0.41%
Total Liabilities
2.7B
↓ 2.92%
Q1 FY23Q/Q Change
Total Assets
3.4B
↑ 9.51%
Total Liabilities
3.1B
↑ 10.32%
Q2 FY23Q/Q Change
Total Assets
3.1B
↓ 9.94%
Total Liabilities
2.7B
↓ 12.99%
Q3 FY23Q/Q Change
Total Assets
3.0B
↓ 1.25%
Total Liabilities
2.7B
↑ 0.1%
Q4 FY23Q/Q Change
Total Assets
3.1B
↑ 3.09%
Total Liabilities
2.7B
↑ 1.04%
Q1 FY24Q/Q Change
Total Assets
3.1B
↓ 2.26%
Total Liabilities
2.6B
↓ 2.1%
Q2 FY24Q/Q Change
Total Assets
3.1B
↓ 0.06%
Total Liabilities
2.6B
↑ 0.18%
FY18Y/Y Change
Operating Cash Flow
119.6M
↑ 557.41%
Investing Cash Flow
96.6M
↓ 1842.49%
Financing Cash Flow
-191.9M
↑ 7338.41%
FY19Y/Y Change
Operating Cash Flow
149.0M
↑ 24.65%
Investing Cash Flow
-57.3M
↓ 159.25%
Financing Cash Flow
-126.0M
↓ 34.31%
FY20Y/Y Change
Operating Cash Flow
120.6M
↓ 19.09%
Investing Cash Flow
-158.7M
↑ 177.16%
Financing Cash Flow
73.4M
↓ 158.27%
FY21Y/Y Change
Operating Cash Flow
281.5M
↑ 133.48%
Investing Cash Flow
-159.8M
↑ 0.72%
Financing Cash Flow
-117.3M
↓ 259.72%
FY22Y/Y Change
Operating Cash Flow
278.0M
↓ 1.27%
Investing Cash Flow
-181.9M
↑ 13.8%
Financing Cash Flow
197.8M
↓ 268.61%
Q1 FY23Q/Q Change
Operating Cash Flow
33.9M
↓ 66.77%
Investing Cash Flow
-45.0M
↓ 37.32%
Financing Cash Flow
273.9M
↑ 37.48%
Q2 FY23Q/Q Change
Operating Cash Flow
-336.6M
↓ 1093.7%
Investing Cash Flow
-53.1M
↑ 18.16%
Financing Cash Flow
-710.0K
↓ 100.26%

Technicals Summary

Sell

Neutral

Buy

Sotera Health Co is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Sotera Health Co
Sotera Health Co
-8.33%
32.53%
8.53%
-38.99%
-38.65%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-1.0%
-8.52%
7.53%
-22.4%
74.89%
Agilent Technologies Inc.
Agilent Technologies Inc.
4.72%
-1.89%
29.95%
-3.61%
96.83%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-4.02%
1.06%
20.02%
2.9%
115.34%
Danaher Corp.
Danaher Corp.
-1.57%
7.61%
23.1%
-10.02%
95.93%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-5.87%
-7.59%
13.62%
-5.64%
55.74%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Sotera Health Co
Sotera Health Co
112.86
112.86
1.61
0.72
0.1
0.08
NA
1.49
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
46.96
46.96
5.03
10.59
0.63
0.23
NA
19.16
Agilent Technologies Inc.
Agilent Technologies Inc.
30.06
30.06
3.11
5.24
0.25
0.08
0.01
20.53
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
36.89
36.89
2.22
21.73
0.14
0.05
0.0
124.17
Danaher Corp.
Danaher Corp.
49.5
49.5
2.66
7.59
0.08
0.04
0.0
68.92
Iqvia Holdings Inc.
Iqvia Holdings Inc.
29.41
29.41
1.12
11.2
0.23
0.05
NA
36.83
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Sotera Health Co
Sotera Health Co
Buy
$4.5B
-38.65%
112.86
3.65%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$38.9B
74.89%
46.96
22.34%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$41.6B
96.83%
30.06
21.75%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$227.5B
115.34%
36.89
14.69%
Danaher Corp.
Danaher Corp.
Buy
$194.1B
95.93%
49.5
17.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.2B
55.74%
29.41
9.39%

Insights on Sotera Health Co

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 248.17M → 276.59M (in $), with an average increase of 10.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 6.32M → 8.75M (in $), with an average increase of 27.8% per quarter

  • Vs A

    In the last 1 year, Agilent Technologies Inc. has given 30.0% return, outperforming this stock by 21.5%

  • Vs TMO

    In the last 3 years, Sotera Health Co has experienced a drawdown of -40.1%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 34.9%

Institutional Holdings

  • Warburg Pincus LLC

    31.36%

  • GTCR LLC

    20.91%

  • HHG PLC

    5.12%

  • Vanguard Group Inc

    4.35%

  • BlackRock Inc

    4.04%

  • Sachem Head Capital Management LP

    2.79%

Company Information

sotera health company provides sterilization, and lab testing and advisory services to the medical device, pharmaceutical, and food products industries in the united states and internationally. its sterilization services include gamma and electron beam irradiation, and eo processing; and lab services comprise analytical chemistry, medical device, and pharmaceutical lab testing, as well as microbiology testing. the company also provides co-60 and gamma irradiators, which are principal components to the gamma sterilization process. its microbiology testing services help customers to identify and measure the potential risks of microbes to a product and ensure that the quality of the products is maintained; and advisory services help customers in navigating the regulatory requirements applicable throughout the product lifecycle. the company was formerly known as sotera health topco, inc. and changed its name to sotera health company in october 2020. sotera health company was incorporated i

Organization
Sotera Health Co
Employees
3000
CEO
Mr. Michael B. Petras Jr.
Industry
Commercial Services

Discover More

FAQs